Internal Medicine, Medical Oncology · Merritt Island, FL
NPI
1528144581
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
325 S Courtenay Pkwy
Merritt Island, FL, 32952
Phone (321) 268-4200
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.9M
336,639 services
Medicare patients, 2024
1,275
Average age 76
Drug cost, 2024
$4.5M
2,049 prescriptions
Company payments, 2025
$198
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Long H Dang was code J1439 (injection, ferric carboxymaltose, 1 mg), 38,250 times for 35 patients. In total Long H Dang billed 336,639 services in 168 codes, and Medicare paid $4.9M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-06-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 38,250 | 35 | $0.87 | $33K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 37,740 | 55 | $0.27 | $10K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 17,700 | 29 | $0.11 | $1,941 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 12,200 | 21 | $39.88 | $487K |
| J3262 Injection, tocilizumab, 1 mg | Office | 10,870 | 11 | $4.72 | $51K |
| J1756 Injection, iron sucrose, 1 mg | Office | 9,500 | 21 | $0.18 | $1,686 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 9,180 | 12 | $39.32 | $361K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 8,830 | 70 | $5.74 | $51K |
| J9025 Injection, azacitidine, 1 mg | Office | 8,100 | 12 | $0.29 | $2,348 |
| J0897 Injection, denosumab, 1 mg | Office | 7,020 | 69 | $20.46 | $144K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 4,145 | 17 | $34.98 | $145K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,796 | 56 | $0.09 | $253 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,950 | 42 | $0.73 | $1,423 |
| 99214 Office E&M - Established | Office | 1,081 | 509 | $90.64 | $98K |
| 99215 Office E&M - Established | Office | 888 | 228 | $132.12 | $117K |
By year: 2022 $3.4M for 219,315 services; 2023 $4.3M for 295,960 services; 2024 $4.9M for 336,639 services.
Medicare prescription drug claims, 2024
In 2024, the drug Long H Dang prescribed most often to Medicare patients was Letrozole, with 101 prescriptions and refills. In total Long H Dang wrote 2,049 Medicare prescriptions that cost $4.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 101 | 248 | 32 | $2,472 |
| Eliquis Apixaban | 91 | 165 | 26 | $91K |
| Anastrozole Generic | 80 | 232 | 27 | $2,232 |
| Oxycodone Hcl Generic | 74 | 74 | 24 | $1,076 |
| Xarelto Rivaroxaban | 68 | 104 | 16 | $56K |
| Dabigatran Etexilate Dabigatran Etexilate Mesylate | 68 | 131 | 20 | $17K |
| Tramadol Hcl Generic | 63 | 67 | 29 | $480 |
| Levothyroxine Sodium Generic | 58 | 152 | 23 | $891 |
| Xtandi Enzalutamide | 56 | 56 | Under 11 | $670K |
| Alprazolam Generic | 46 | 47 | 13 | $308 |
| Morphine Sulfate Er Morphine Sulfate | 43 | 43 | Under 11 | $970 |
| Gabapentin Generic | 40 | 56 | 12 | $614 |
| Acyclovir Generic | 39 | 81 | Under 11 | $554 |
| Duloxetine Hcl Generic | 38 | 76 | 22 | $1,204 |
| Lorazepam Generic | 37 | 37 | 11 | $191 |
Brand drugs: 563 claims; generic drugs: 1,486 claims; opioid claims: 251.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Long H Dang $198 ($198 in general payments such as food, travel and fees) from 3 companies. The largest payer was Janssen Biotech, Inc. with $124.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.